Thursday, April 23, 2015, Orlando, FL, 6:15 AM – 7:45 AM (Eastern Time)

Oncology Tumor Panel Series: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty

Part 2: Multiple Myeloma

Preregistration is now closed for this session. For standby registration information please click the Registration tab below for further instructions.

If you would like to receive information on additional CNE opportunities or other oncology education programs produced by Research To Practice, including the edited proceedings from all of our ONS satellites, please visit our subscription page to join our email and mail lists.

Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819
Hotel Phone: (407) 284-1234

Meeting Room:
Florida Ballroom (C Level)

Time:
6:15 AM – 7:45 AM

Breakfast buffet will be available for those attending the event.

Faculty:

Rafael Fonseca, MD
Getz Family Professor of Cancer
Chair, Department of Internal Medicine
Mayo Clinic Arizona
Scottsdale, Arizona

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Director of Translational Research
B-Cell Malignancy Program
Department of Hematology and
Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia


Kimberly Noonan, RN, ANP, AOCN
Chief Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Tiffany Richards, MS, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Meeting space has been assigned to provide a Satellite Symposium supported by Onyx Pharmaceuticals, an Amgen subsidiary and Takeda Oncology via educational grants during the Oncology Nursing Society’s (ONS) 40th Annual Congress, April 23-26, 2015 in Orlando, Florida. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement, nor does the Oncology Nursing Society assume any responsibility for the educational content of the symposium.

A young man with newly diagnosed multiple myeloma undergoes an autologous stem cell transplant (ASCT)
CASE 1:
A 53-year-old man was diagnosed with standard-risk, Stage III multiple myeloma. He achieved a very good partial response after 3 cycles of lenalidomide/bortezomib/dexamethasone (RVD) and underwent ASCT followed by maintenance therapy with ixazomib/lenalidomide on a clinical trial. He has cut back on the volume of his dental practice to part-time because of fatigue, and he flies to and from his medical appointments. (Ms Richards)

DISCUSSION TOPICS:

  • Prognosis for patients with standard-risk multiple myeloma in the current treatment era
  • Selection of induction therapy for transplant-eligible patients with standard-risk disease
  • Indications for and selection and duration of post-transplant maintenance therapy
  • Management of side effects and toxicities associated with currently approved and investigational proteasome inhibitors and immunomodulatory agents (IMiDs)
  • Emerging Phase III data with the oral proteasome inhibitor ixazomib and potential role in clinical practice
  • Incidence of ixazomib-associated peripheral neuropathy

A young woman with a history of severe anxiety and depression is diagnosed with high-risk multiple myeloma
CASE 2:
A 53-year-old woman with multiple comorbidities who had been on disability due to anxiety and depression was diagnosed with high-risk multiple myeloma and a left rib fracture in 2014. She received induction carfilzomib/lenalidomide/dexamethasone and complained of dyspnea without medical correlates. She tolerated ASCT well, with the exception of anxiety, tachycardia, neutropenia and fever. Plans are under way to initiate maintenance carfilzomib/lenalidomide therapy. (Ms Noonan)

DISCUSSION TOPICS:

  • Role of common genetic abnormalities in patient risk assessment and therapeutic decision-making
  • Similarities and differences between bortezomib and carfilzomib
  • Available data with and current use of carfilzomib as a component of induction therapy
  • Selection of maintenance therapy for patients with high-risk multiple myeloma
  • Incidence of pulmonary and/or cardiac toxicity with carfilzomib and implications for clinical management
  • Rational hydration and fluid monitoring strategies for patients receiving carfilzomib

An 80-year-old widow is diagnosed with multiple myeloma and multiple lytic bone lesions
CASE 3:
An active 80-year-old widow with 2 supportive adult sons was diagnosed in late 2014 with Stage III, standard-risk multiple myeloma with multiple lytic lesions. She received RVD and achieved a partial remission after 2 cycles, after which lenalidomide was reduced to 15 mg/day. (Ms Richards)

DISCUSSION TOPICS:

  • Implications of the FIRST trial comparing limited or continuous Rd (lenalidomide/low-dose dexamethasone) to MPT (melphalan/prednisone/thalidomide) and current role of melphalan
  • Use of 3-drug induction regimens in the nontransplant setting
  • Definition and duration of maintenance therapy for patients not undergoing transplant
  • Long-term risks associated with maintenance therapy
  • Thromboprophylaxis in patients receiving IMiDs
  • Preemptive dose reduction to maintain patients on active therapy
  • Bisphosphonates in patients with and without documented bone disease; duration of treatment

A woman with relapsed disease who achieves a durable complete remission (CR) with the newer-generation proteasome inhibitor oprozomib on a clinical trial
CASE 4:
A 62-year-old woman presented with multiple myeloma, fatigue, lymphadenopathy and lower back pain in 2006. She received lenalidomide and low-dose dexamethasone, achieved a CR and underwent stem cell collection. She was monitored off therapy until disease progression in April 2008, when she received bortezomib/dexamethasone. After disease progression in January 2011 she enrolled on a clinical trial of oprozomib and achieved a CR in August 2013. Currently, she remains in CR and continues to receive the extended-release formulation of oprozomib. She travels monthly from New York to Boston for treatment, works full-time as an administrator in a medical clinic and cares for her 93-year-old mother while living with her husband, son, daughter-in-law and grandson. (Ms Noonan)

DISCUSSION TOPICS:

  • Selection of patients for ASCT and early versus delayed timing of ASCT in newly diagnosed multiple myeloma
  • Sequencing available therapeutic options in patients with relapsed/refractory disease
  • Use of carfilzomib in combination with pomalidomide in relapsed/refractory disease
  • FDA approval of panobinostat and integration into current clinical practice
  • Administration, efficacy and side effects of oprozomib
  • Other novel therapies under investigation in multiple myeloma (daratumumab, elotuzumab, et cetera)


Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of MM.

Learning Objectives and Goals

  • Compare and contrast the benefits and risks of evidence-based treatment regimens, and appropriately sequence available therapies in the long-term care of patients with active MM.
  • Develop supportive care algorithms to both recognize and manage side effects attributable to proteasome inhibitors and IMiDs.
  • Counsel individuals regarding the rationale for the use of maintenance therapeutic approaches in the post-transplant and nontransplant settings, focusing on the role of patient- and disease-related factors, including cytogenetic profile.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with MM to improve clinical and quality-of-life outcomes.

Accreditation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

To obtain a certificate of completion and receive credit for this event, attendees must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International clinicians, please note: In order for a certificate of completion to be issued, you must provide a valid email address.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Noonan has no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FonsecaAdvisory Committee: Applied Bioscience, Bristol-Myers Squibb Company; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Sanofi; Contracted Research: Amgen Inc, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi. Dr LonialAdvisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi, Takeda Oncology. Ms RichardsConsulting Agreements: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This activity is supported by educational grants from Onyx Pharmaceuticals, an Amgen subsidiary and Takeda Oncology.

Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819
Hotel Phone: (407) 284-1234

Meeting Room:
Florida Ballroom (C Level)

Directions:
The Hyatt Regency Orlando hotel is conveniently located within walking distance (5 to 10 minutes) of the Orange County Convention Center and is the host hotel for the ONS 40th Annual Congress.

» View directions

 
Thank you for your interest in our CNE program. At this time preregistration is closed for this event as we have reached seating capacity. Onsite standby registration will be open starting at 5:15 AM on Thursday, April 23. If you are interested in standby registration, please visit our onsite registration desk located outside the Florida Ballroom (C Level) at the Hyatt Regency Orlando, Orlando, Florida (9801 International Drive).

If seats become available for the program, we will accept standby registrations on a first come, first served basis prioritized for healthcare professionals directly involved in the care of patients.

Please note, standby registration DOES NOT GUARANTEE participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.